Online citations, reference lists, and bibliographies.
← Back to Search

Malignant Pleural Mesothelioma: Update, Current Management, And Newer Therapeutic Strategies.

M. Pistolesi, J. Rusthoven
Published 2004 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The diagnosis and management of malignant pleural mesothelioma are major challenges that often frustrate both patient and clinician alike. Occupational asbestos exposure to crocidolite or amosite forms of the fiber is the most important known risk factor in North America and Western Europe. Other mineral fibers such as erionite, a naturally occurring fibrous zeolite crystal, are associated with mesothelioma in volcanic tuffs of the Cappadocia region of central Anatolia in Turkey. In addition, other possible factors such as the presence of simian virus 40 and genetic susceptibility have been associated recently with the development of mesothelioma in animal models. These latter findings are increasing our understanding of this disease. In addition, the discovery of elevated levels of various markers such as folic acid receptor alpha, cyclooxygenase 2, and multidrug resistance proteins 1 and 2 in mesothelioma tissue have opened up new areas of potential diagnostic and therapeutic importance. However, traditional treatment modalities--surgery, radiotherapy, and chemotherapy--have evolved slowly, and few gains in therapeutic efficacy have occurred. Recently, however, continuing research efforts have led to novel treatment strategies that are changing the way clinicians view a disease that has traditionally been managed with almost universal therapeutic nihilism. This review explores our current knowledge of this disease and presents current and novel therapeutic strategies.
This paper references
10.1007/BF02303746
Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma
H. Pass (2006)
10.1136/thx.31.1.15
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)
10.1002/(SICI)1097-0142(19981115)83:10<2099::AID-CNCR8>3.0.CO;2-3
Intrapleural administration of interleukin‐2 for the treatment of patients with malignant pleural mesothelioma
P. Astoul (1998)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1016/S0169-5002(01)00250-1
High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631.
M. Kosty (2001)
10.1016/S0169-5002(03)92480-9
P-513 Improving pulmonary function in patients with malignant pleural mesothelioma: Results of the phase III trial of pemetrexed + cisplatin vs. cisplatin
M. Pistolesi (2003)
10.1023/A:1008379101017
Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors.
A. Adjei (2000)
10.1067/MTC.2001.111176
The α folate receptor is highly activated in malignant pleural mesothelioma
R. Bueno (2001)
10.1002/(SICI)1097-0142(20000415)88:8<1807::AID-CNCR8>3.0.CO;2-L
Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma
W. John (2000)
10.1002/1097-0142(20010801)92:3<650::AID-CNCR1366>3.0.CO;2-0
Combined regimen of cisplatin, doxorubicin, and α‐2b interferon in the treatment of advanced malignant pleural mesothelioma
H. Parrà (2001)
10.1136/thx.39.4.255
Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients.
M. Law (1984)
10.1200/JCO.1999.17.10.3009
Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin.
R. Thödtmann (1999)
10.2214/AJR.172.4.10587144
Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.
R. Heelan (1999)
10.1038/sj.bjc.6600118
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
J. van Haarst (2002)
10.1093/OXFORDJOURNALS.ANNONC.A058846
Weekly high-dose cisplatin in malignant pleural mesothelioma.
A. Planting (1994)
Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.
C. Niyikiza (2002)
Phase II trial of mitomycin in malignant mesothelioma.
D. Bajorin (1987)
10.1200/JCO.1994.12.6.1156
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
V. Rusch (1994)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1016/S0003-4975(96)00808-9
Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion.
A. Yim (1996)
10.1634/THEONCOLOGIST.6-4-363
Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors.
A. Hanauske (2001)
10.1053/SONC.2002.30230
Multimodality treatment of diffuse malignant pleural mesothelioma.
L. Zellos (2002)
A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas.
J. Testa (1998)
10.3816/CLC.2004.N.020
Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group.
C. Belani (2004)
10.1136/oem.50.6.485
Mortality from lung cancer in asbestos workers 1955.
R. Doll (1955)
10.1097/00001813-200004000-00005
Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma - a feasibility study
A. Knuuttila (2000)
10.1097/00004728-199505000-00006
CT‐Guided Pleural Needle Biopsy in the Diagnosis of Malignant Mesothelioma
M. Metintas (1995)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
10.1093/OXFORDJOURNALS.AJE.A009093
Analysis of current trends in United States mesothelioma incidence.
B. Price (1997)
10.1023/A:1012292230480
The expression of P-glycoprotein and multidrug resistance proteins 1 and 2 (MRP1 and MRP2) in human malignant mesothelioma.
Y. Soini (2001)
10.1053/SONC.2002.30234
New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents.
A. Nowak (2002)
10.1136/THX.52.6.507
Malignant mesothelioma in south east England: clinicopathological experience of 272 cases.
D. Yates (1997)
10.1016/S0046-8177(98)90006-5
Ultrastructural features of diffuse malignant mesotheliomas.
T. Oury (1998)
10.1136/thorax.55.9.731
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
J. Edwards (2000)
10.1200/JCO.1999.17.4.1194
Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.
J. Rusthoven (1999)
10.1093/AJCP/110.3.397
Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review.
D. Henderson (1998)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1200/JCO.1999.17.1.25
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
10.1164/AJRCCM.153.1.8542156
Black spots concentrate oncogenic asbestos fibers in the parietal pleura. Thoracoscopic and mineralogic study.
C. Boutin (1996)
10.1200/JCO.1990.8.1.151
Phase II trial of carboplatin in the management of malignant mesothelioma.
D. Raghavan (1990)
Evaluation of membranous staining of mesothelioma.
J. King (1998)
10.1378/CHEST.108.3.754
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
10.1016/S0093-7754(02)70217-0
Future directions in the development of pemetrexed.
H. Calvert (2002)
Extrapleural pneumonectomy for malignant mesothelioma.
D. Sugarbaker (1997)
10.1016/0003-4975(93)90983-O
Complications of thoracoscopy.
L. Kaiser (1993)
10.1093/ANNONC/MDF046
Malignant pleural mesothelioma: a phase II trial with docetaxel.
D. Vorobiof (2002)
10.1002/1097-0142(19831201)52:11<1981::AID-CNCR2820521102>3.0.CO;2-P
Malignant mesothelioma. The eastern cooperative oncology group (ECOG) experience
H. Lerner (1983)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1053/SONC.2002.30231
Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine.
P. Baas (2002)
10.1023/A:1008346925273
Caelyx in malignant mesothelioma: a phase II EORTC study.
P. Baas (2000)
Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma.
V. Rusch (1997)
10.1038/bjc.1996.465
Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.
J. Van Meerbeeck (1996)
Latency periods in asbestos-related mesothelioma of the pleura.
C. Bianchi (1997)
10.1016/S0140-6736(00)04013-7
Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey
Iman Roushdy-Hammady (2001)
10.1378/CHEST.103.1.209
Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion.
P. Astoul (1993)
10.1002/(SICI)1097-0142(19991115)86:10<1985::AID-CNCR15>3.0.CO;2-H
Edatrexate (10‐ethyl‐deaza‐aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma
H. Kindler (1999)
10.1002/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.0.CO;2-S
A phase II study of gemcitabine in patients with malignant pleural mesothelioma
J. van Meerbeeck (1999)
10.1038/sj.bjc.6690105
The European mesothelioma epidemic
J. Peto (1999)
10.7326/0003-4819-96-6-746
Diffuse malignant mesothelioma. Prospective evaluation of 69 patients.
A. Chahinian (1982)
10.3816/CBC.2001.N.010
Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis.
M. Spielmann (2001)
10.1200/JCO.2000.18.23.3912
Phase II study of vinorelbine in patients with malignant pleural mesothelioma.
J. Steele (2000)
10.1002/1097-0142(19801215)46:12<2736::AID-CNCR2820461233>3.0.CO;2-L
Latency of asbestos disease among insulation workers in the United States and Canada
I. Selikoff (1980)
10.1007/BF00685720
Carboplatin in malignant mesothelioma: A phase II study of the cancer and leukemia Group B
N. Vogelzang (2004)
10.1200/JCO.1988.6.3.527
Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers.
A. Alberts (1988)
10.1006/SCBI.2000.0349
Prospects for an SV40 vaccine.
M. Imperiale (2001)
10.1200/JCO.2002.10.073
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.
A. Hughes (2002)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1093/JNCI/78.6.1053
Demographic patterns for mesothelioma in the United States.
R. Connelly (1987)
10.1002/1097-0142(19840915)54:6<961::AID-CNCR2820540602>3.0.CO;2-B
Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single‐agent 5‐fluorouracil and adriamycin
V. Harvey (1984)
10.1007/BF00175403
A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group Study
B. Zidar (2004)
10.3892/IJO.18.2.425
Mutational analysis of N-ras, p53, p16INK4a, p14ARF and CDK4 genes in primary human malignant mesotheliomas.
T. Papp (2001)
10.1136/oem.17.4.260
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
J. Wagner (1960)
LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
C. Shih (1997)
10.1038/bjc.1992.200
High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study.
O. Solheim (1992)
10.1073/PNAS.170207097
Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity.
M. Bocchetta (2000)
10.1007/978-1-4615-1589-0_13
Malignant pleural mesothelioma.
L. Ho (2001)
10.1023/A:1008236010868
Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma.
George W. Middleton (1998)
10.1016/S0093-7754(02)70209-1
Folate status and the safety profile of antifolates.
H. Calvert (2002)
10.1038/sj.bjc.6690597
High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma
M. Halme (1999)
10.1200/JCO.2003.06.122
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
G. Scagliotti (2003)
10.1073/PNAS.92.24.10854
High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.
A. Bianchi (1995)
10.1378/CHEST.116.SUPPL_3.450S
Pleuropneumonectomy in the treatment of malignant pleural mesothelioma.
S. Grondin (1999)
10.1200/JCO.20.1.274
Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.
S. Mikulski (2002)
10.1097/00000478-199810000-00006
Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
N. Ordóñez (1998)
10.1016/S0959-8049(01)00428-2
A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma.
J. Van Meerbeeck (2002)
10.1016/0360-3016(82)90379-0
Radiation therapy in the management of patients with mesothelioma.
W. Gordon (1982)
10.1183/09031936.97.10102383
Pleurodesis in malignant pleural effusions: a randomized study of tetracycline versus bleomycin.
E. Martínez-Moragón (1997)
10.1002/1098-2264(2000)9999:9999<::AID-GCC1019>3.0.CO;2-B
Simian virus‐40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma
A. Procopio (2000)
10.1016/S0169-5002(99)00030-6
Ifosfamide in malignant mesothelioma: a phase II study.
M. Andersen (1999)
10.1016/S0959-8049(00)00139-8
Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma.
K. Fizazi (2000)
10.1016/0003-4975(94)91066-9
Aggressive multimodality therapy for malignant pleural mesothelioma.
T. Rice (1994)
10.1177/030089169107700112
Epirubicin in the Treatment of Malignant Mesothelioma: A Phase II Cooperative Study
M. Magri (1991)
10.1378/CHEST.110.6.1387
Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases.
J. Viallat (1996)
10.1002/1097-0142(19930715)72:2<389::AID-CNCR2820720213>3.0.CO;2-V
Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 1: Diagnosis
C. Boutin (1993)
Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma.
J. Edwards (2002)



This paper is referenced by
Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma.
Y. Matsuzaki (2008)
10.1007/s11060-006-9215-0
Perineural Spread of Malignant Mesothelioma Resulting in an Intradural Spinal Cord Mass: Case Report
V. Hillard (2006)
10.1080/02656730601012508
Hyperthermia combined with intra-thoracic chemotherapy and radiotherapy for malignant pleural mesothelioma
Hongqiang Xia (2006)
ROLE D'ENDOCAN DANS LA CROISSANCE TUMORALE ET EFFETS DES ANTICORPS ANTI-ENDOCAN SUR LE DEVELOPPEMENT TUMORAL
B. Grigoriu (2006)
10.14789/PJMJ.52.347
Diagnosis and medical treatment of malignant mesothelioma
K. Takahashi (2006)
Computer-Assisted Diagnosis for Early Stage Pleural Mesothelioma: Automated Extraction of Pleura to Detect Pleural Thickenings from Thoracic CT Images
K. Chaisaowong (2007)
10.1097/JTO.0b013e31819f2e0e
Screening for Malignant Pleural Mesothelioma and Lung Cancer in Individuals with a History of Asbestos Exposure
H. Roberts (2009)
10.1016/J.RMED.2006.06.028
Identification of a mesothelioma phenotype.
J. Ohar (2007)
10.1016/J.LUNGCAN.2005.06.006
Radiation recall dermatitis with pemetrexed.
J. Hureaux (2005)
10.1016/J.BIOCEL.2006.07.002
Human malignant mesothelioma: molecular mechanisms of pathogenesis and progression.
E. P. Spugnini (2006)
10.1016/B978-343756420-8.50021-4
Kapitel 13 – Tumoren der Lunge und des Mediastinums
Joachim Preiss (2006)
10.1097/JTO.0b013e31817c73d6
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
A. Santoro (2008)
10.1201/9781420038149.CH5
The Pathologic Features of Asbestos-Induced Disease
S. Hammar (2005)
10.1055/s-0033-1361589
Sarcomatoid Malignant Mesothelioma Presenting with Intramedullary Spinal Cord Metastasis: A Case Report and Literature Review
Junkoh Yamamoto (2014)
10.14311/1432
3D Surface-based Detection of Pleural Thickenings
P. Faltin (2011)
10.1097/COC.0b013e3181d31f02
Expert Opinions of the First Italian Consensus Conference on the Management of Malignant Pleural Mesothelioma
C. Pinto (2011)
10.4172/1948-5956.1000147
Malignant Mesothelioma of Peritoneum: About a Case with Review of the Literature
H. Berhil (2012)
10.4161/cbt.20553
Increased frequency of circulating invariant natural killer T cells in malignant pleural mesothelioma patients
Emanuela Altomare (2012)
10.1039/c3lc51093j
A microfluidic platform for chemoresistive testing of multicellular pleural cancer spheroids.
Janine Ruppen (2014)
10.1016/j.yexmp.2010.10.008
MT1-MMP plays an important role in an invasive activity of malignant pleural mesothelioma cell.
T. Doi (2011)
10.1007/s00104-010-1926-2
Zytoreduktive Chirurgie und hypertherme intrathorakale Chemotherapieperfusion
H. Hofmann (2010)
10.1109/ECTICON.2008.4600477
Detection and follow-up assessment of pleural thickenings from 3D CT data
K. Chaisaowong (2008)
10.2147/TCRM.S1603
Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma
Ranjit K Goudar (2008)
Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma.
V. Ambrosini (2005)
10.1378/CHEST.128.2.1068
Malignant pleural mesothelioma with less-frequent features.
E. Antón (2005)
10.1201/9781420038149.CH7
Clinical Diagnosis of Asbestos-Related Disease
G. Friedman (2005)
10.1111/j.1759-7714.2010.00033.x
Malignant pleural mesothelioma: A retrospective analysis of clinicopathological and survival data
Azza M. Adel (2011)
10.1016/J.CLINIMAG.2005.12.027
Computed tomography findings in 66 patients with malignant pleural mesothelioma due to environmental exposure to asbestos.
F. Okten (2006)
Radiotherapy for malignant pleural mesothelioma (Review)
E. Chapman (2010)
10.1371/journal.pone.0023569
Apoptosis Induced by Piroxicam plus Cisplatin Combined Treatment Is Triggered by p21 in Mesothelioma
A. Baldi (2011)
10.1016/j.tiv.2011.05.023
In vitro screening of synergistic ascorbate-drug combinations for the treatment of malignant mesothelioma.
S. Martinotti (2011)
10.5220/0005718702330243
Flattening of the Lung Surface with Temporal Consistency for the Follow-Up Assessment of Pleural Mesothelioma
P. Faltin (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar